Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

64.54 -5.67 (-8.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,230,228
Open 71.07
Bid (Size) 65.30 (4)
Ask (Size) 65.50 (1)
Prev. Close 70.21
Today's Range 61.55 - 76.97
52wk Range 37.55 - 76.97
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
Exposures Product Safety
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Fossil Fuels

Performance

YTD
+57.41%
+57.41%
1 Month
+17.95%
+17.95%
3 Month
+29.24%
+29.24%
6 Month
+9.50%
+9.50%
1 Year
+27.80%
+27.80%

More News

Read More
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
Via The Motley Fool
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Via InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
Via The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
Via The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Via InvestorPlace
The Latest Analyst Ratings for CRISPR Therapeutics
Via Benzinga
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
Via Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
Via The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Five Best Performing Stocks Of The Top ETF Of November
Via Talk Markets
Topics ETFs
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
Via The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.